drugset / Trial / NCT03115853

The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function

NCT03115853

Phase 4 Completed 31 enrolled Vanderbilt University Medical Center
RandomizedCrossoverSingle-blindDiagnostic

Summary

Aliskiren (also called TekturnaTM) is a new drug for high blood pressure. Aliskiren works by blocking the actions of a substance called renin. Renin is a natural substance in the body that raises blood pressure. Renin is believed to contribute to the production of blood clots by increasing the amount of a substance known as Plasminogen Activator Inhibitor or PAI-1. This study will measure how aliskiren changes the amount of PAI-1 in the blood depending on the time of dosing. The purpose of this study is to find out if it is better to take aliskiren in the morning or at night.

Timeline

Start
2009-06
Primary completion
2012-01
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 150 mg Oral
Subject Aliskiren Small molecule 300 mg Oral
Background Hydrochlorothiazide Unknown 25 mg Oral

Indications